<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>AGONIST-ANTAGONIST OPIOIDS</b></p>

<p><b>From the French ANSM drug interactions document of September 2016, pp. 162</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>AGONIST-ANTAGONIST OPIOIDS </b></p>

<p><b>CLASS CODE: </b></p>

<p><b>NO2A-001</b></p></td>
<td valign="top"><p><b>STEP II OPIOID ANALGESICS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>N02A-003</b></p></td>
<td valign="top"><p>Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome. </p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>AGONIST-ANTAGONIST OPIOIDS </b></p>

<p><b>CLASS CODE: </b></p>

<p><b>NO2A-001</b></p></td>
<td valign="top"><p><b>STEP III OPIOID ANALGESICS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>N02A-002</b></p></td>
<td valign="top"><p>Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>AGONIST-ANTAGONIST OPIOIDS </b></p>

<p><b>CLASS CODE: </b></p>

<p><b>NO2A-001</b></p></td>
<td valign="top"><p><b>TRUE MORPHINE ANTITUSSIVES</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>R0GDA0-002</b></p></td>
<td valign="top"><p>Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome</p></td>
<td valign="top"><p><b>Not recommended </b></p></td>
</tr>

<tr>
<td valign="top"><p><b>AGONIST-ANTAGONIST OPIOIDS </b></p>

<p><b>CLASS CODE: </b></p>

<p><b>NO2A-001</b></p></td>
<td valign="top"><p><b>METHADONE</b></p>

<p><b>RxNorm: 6813 </b></p>

<p><b>ATC: N07BC02</b></p></td>
<td valign="top"><p>Decrease of the effect of the methadone due to competitive blocking of the receptors</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>AGONIST-ANTAGONIST OPIOIDS </b></p>

<p><b>CLASS CODE: </b></p>

<p><b>NO2A-001</b></p></td>
<td valign="top"><p><b>PARTIAL AGONIST OPIOIDS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>PARAG</b></p></td>
<td valign="top"><p>Risk of decrease of the antalgic effect and/or of appearance of a withdrawal syndrome</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

</tbody>
</table>

